146 related articles for article (PubMed ID: 27587584)
1. Structures of mithramycin analogues bound to DNA and implications for targeting transcription factor FLI1.
Hou C; Weidenbach S; Cano KE; Wang Z; Mitra P; Ivanov DN; Rohr J; Tsodikov OV
Nucleic Acids Res; 2016 Oct; 44(18):8990-9004. PubMed ID: 27587584
[TBL] [Abstract][Full Text] [Related]
2. Allosteric interference in oncogenic FLI1 and ERG transactions by mithramycins.
Hou C; Mandal A; Rohr J; Tsodikov OV
Structure; 2021 May; 29(5):404-412.e4. PubMed ID: 33275876
[TBL] [Abstract][Full Text] [Related]
3. Solution structure of mithramycin dimers bound to partially overlapping sites on DNA.
Sastry M; Fiala R; Patel DJ
J Mol Biol; 1995 Sep; 251(5):674-89. PubMed ID: 7666419
[TBL] [Abstract][Full Text] [Related]
4. Dimerization and DNA recognition rules of mithramycin and its analogues.
Weidenbach S; Hou C; Chen JM; Tsodikov OV; Rohr J
J Inorg Biochem; 2016 Mar; 156():40-7. PubMed ID: 26760230
[TBL] [Abstract][Full Text] [Related]
5. Structural Basis for Dimerization and DNA Binding of Transcription Factor FLI1.
Hou C; Tsodikov OV
Biochemistry; 2015 Dec; 54(50):7365-74. PubMed ID: 26618620
[TBL] [Abstract][Full Text] [Related]
6. FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements.
Watson DK; Robinson L; Hodge DR; Kola I; Papas TS; Seth A
Oncogene; 1997 Jan; 14(2):213-21. PubMed ID: 9010223
[TBL] [Abstract][Full Text] [Related]
7. Cooperative DNA binding with AP-1 proteins is required for transformation by EWS-Ets fusion proteins.
Kim S; Denny CT; Wisdom R
Mol Cell Biol; 2006 Apr; 26(7):2467-78. PubMed ID: 16537893
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript.
Grohar PJ; Glod J; Peer CJ; Sissung TM; Arnaldez FI; Long L; Figg WD; Whitcomb P; Helman LJ; Widemann BC
Cancer Chemother Pharmacol; 2017 Sep; 80(3):645-652. PubMed ID: 28735378
[TBL] [Abstract][Full Text] [Related]
9. A polypeptide from the junction region sequence of EWS-FLI1 inhibits Ewing's sarcoma cells, interacts with the EWS-FLI1 and partner proteins.
Thangaretnam KP; Gopisetty G; Ramanathan P; Rajkumar T
Sci Rep; 2017 Aug; 7(1):7172. PubMed ID: 28775288
[TBL] [Abstract][Full Text] [Related]
10. Single-chain antibodies to the EWS NH(2) terminus structurally discriminate between intact and chimeric EWS in Ewing's sarcoma and interfere with the transcriptional activity of EWS in vivo.
Aryee DN; Kreppel M; Bachmaier R; Uren A; Muehlbacher K; Wagner S; Breiteneder H; Ban J; Toretsky JA; Kovar H
Cancer Res; 2006 Oct; 66(20):9862-9. PubMed ID: 17047047
[TBL] [Abstract][Full Text] [Related]
11. RNA helicase A activity is inhibited by oncogenic transcription factor EWS-FLI1.
Erkizan HV; Schneider JA; Sajwan K; Graham GT; Griffin B; Chasovskikh S; Youbi SE; Kallarakal A; Chruszcz M; Padmanabhan R; Casey JL; Üren A; Toretsky JA
Nucleic Acids Res; 2015 Jan; 43(2):1069-80. PubMed ID: 25564528
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.
Selvanathan SP; Graham GT; Erkizan HV; Dirksen U; Natarajan TG; Dakic A; Yu S; Liu X; Paulsen MT; Ljungman ME; Wu CH; Lawlor ER; Üren A; Toretsky JA
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1307-16. PubMed ID: 25737553
[TBL] [Abstract][Full Text] [Related]
13. Mithramycin 2'-Oximes with Improved Selectivity, Pharmacokinetics, and Ewing Sarcoma Antitumor Efficacy.
Liu Y; Eckenrode JM; Zhang Y; Zhang J; Hayden RC; Kyomuhangi A; Ponomareva LV; Cui Z; Rohr J; Tsodikov OV; Van Lanen SG; Shaaban KA; Leggas M; Thorson JS
J Med Chem; 2020 Nov; 63(22):14067-14086. PubMed ID: 33191745
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target.
Remsing LL; Bahadori HR; Carbone GM; McGuffie EM; Catapano CV; Rohr J
Biochemistry; 2003 Jul; 42(27):8313-24. PubMed ID: 12846580
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of DNA recognition by anticancer antibiotics, chromomycin A(3), and mithramycin: roles of minor groove width and ligand flexibility.
Chakrabarti S; Bhattacharyya D; Dasgupta D
Biopolymers; 2000-2001; 56(2):85-95. PubMed ID: 11592055
[TBL] [Abstract][Full Text] [Related]
16. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma.
Tosso PN; Kong Y; Scher L; Cummins R; Schneider J; Rahim S; Holman KT; Toretsky J; Wang K; Üren A; Brown ML
J Med Chem; 2014 Dec; 57(24):10290-303. PubMed ID: 25432018
[TBL] [Abstract][Full Text] [Related]
18. How mithramycin stereochemistry dictates its structure and DNA binding function.
Hou C; Rohr J; Parkin S; Tsodikov OV
Medchemcomm; 2019 May; 10(5):735-741. PubMed ID: 31191864
[TBL] [Abstract][Full Text] [Related]
19. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy.
Albertini V; Jain A; Vignati S; Napoli S; Rinaldi A; Kwee I; Nur-e-Alam M; Bergant J; Bertoni F; Carbone GM; Rohr J; Catapano CV
Nucleic Acids Res; 2006; 34(6):1721-34. PubMed ID: 16571899
[TBL] [Abstract][Full Text] [Related]
20. Solution structure of the mithramycin dimer-DNA complex.
Sastry M; Patel DJ
Biochemistry; 1993 Jul; 32(26):6588-604. PubMed ID: 8329387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
